



# Old age, polymorbidity and stroke, a new epidemic?

**Professor Gary Ford**

**Chief Executive Officer, Oxford Academic Health Science Network**

**Consultant Stroke Physician, Oxford University Hospitals**

**Visiting Professor of Clinical Pharmacology, Oxford University**

**Governing Body Fellow, Green Templeton College**


Swiss Stroke Society

11 Jan 2018


# The Global Burden of Stroke

- Each year 15 million people suffer a stroke worldwide
- 6 million die
- 5 million permanently disabled at increased risk of recurrent stroke, depression and dementia
- Stroke 24% increase in global years of life lost between 1990 and 2013
- Moving from 5<sup>th</sup> to 3<sup>rd</sup> leading cause

GBD 2013 Mortality and causes of death collaboration, Lancet 2015



# EU population pyramid changes 2016-2080




# Population projections for the cantons in Switzerland 2015-2045



Schweizerische Eidgenossenschaft  
Confédération suisse  
Confederazione Svizzera  
Confederaziun svizra

Federal Statistical Office



Source: OFS – SCENARIO

© OFS 2016

Increase (%) of the permanent resident population  $\geq 65$  yrs in the townships from 2015 to 2045


# Population projections for the cantons in Switzerland 2015-2045



Schweizerische Eidgenossenschaft  
Confédération suisse  
Confederazione Svizzera  
Confederaziun svizra

Federal Statistical Office

Large increase expected in number of retired people



Source: OFS - SCENARIO

© OFS 2016




Elderly dependency ratio (number of people > 65 yrs per 100 aged 20-64 yrs) in 2015 and in 2045

# Implications for Stroke Units

- Age profile of patients presenting with acute stroke will change profoundly
  - population demographics
  - successful prevention in middle age
  - reduced mortality following first ever stroke
- Greater proportion of patients presenting with acute stroke will have disability from previous stroke
- Increasing proportion of acute stroke patients will have multiple comorbidities and disability from other conditions such as dementia
- Oxfordshire comparison of median (IQR) age stroke/TIA patients


OCSP	1981-86	74 (64-80) yrs
OXVASC	2002-03	76 (66-83) yrs

# Population 85 years and over: 1992, 2015, 2033



# Age of AIS at CHUV 2003 → 2017

N=4'454 consecutive strokes (median and IQR)




Source: **ASTRA** Strambo & Michel, unpublished




# Aims of Treatment in Older People

- Improve quality of life
- Increase life expectancy



# Primary Stroke Prevention




Preventing stroke moves mortality curve and compresses disability mortality curves

*Adapted from Fries et al, NEJM 1980*


# The impact of interventions for stroke on mortality / disability curves

- Hemicraniectomy
- VTE prevention (IPC sleeves)
- Reperfusion therapies in people dependent pre-stroke (mRS 3-5)
- Hypertension / AF primary prevention
- Reperfusion therapies in people independent pre-stroke (mRS 0-2)



# Co-morbidity Measures

- Comorbidity - the effect of all other diseases an individual patient might have other than the primary disease of interest
- Differences in terminology
  - Cumulative Illness Rating Scale (1968)
  - Cumulative Illness Rating Scale for Geriatrics (1991)
  - The Kaplan-Feinstein Index (1973)
  - Charlson Index (1987)
  - Modified Charlson Index (1992)<sup>1</sup>
  - Elixhauser Index
  - Index of Co-Existent Disease (1993)
  - Geriatric Index of Comorbidity (2002)
  - Functional Comorbidity Index (2005)
  - Total Illness Burden Index (2007)




# Charlson Comorbidity Index

- Predicts ten-year mortality in population studies
- Conditions are assigned a score of 1, 2, 3, or 6, depending on the mortality risk. Many variations have been produced.
- Scores are summed to provide a total score.
  - Age <40yrs 0 points ; >70 yrs 4 points
  - 1 point: Myocardial infarct, congestive heart failure, peripheral vascular disease, dementia, cerebrovascular disease, chronic lung disease, connective tissue disease, ulcer, chronic liver disease, diabetes.
  - 2 point: Hemiplegia, moderate or severe kidney disease, diabetes with end organ damage, tumor, leukemia, lymphoma.
  - 3 points: Moderate or severe liver disease.
  - 6 points: Malignant tumor, metastasis, AIDS

# Morbidity prevalence in the very old

- Newcastle 85+ study population based study
- 710 participants with complete information
- < 1% (n=6) participants had none of the 20 conditions
- 6.5% had one condition
- 8.9% had  $\geq 8$  conditions
- 92.7% multi-morbidity ( $\geq 2$  conditions)
- Women 93.6% vs. men 91.2%  
p= 0.22




# Comorbidities of AIS at CHUV 2003 → 2017

N=4'268 consecutive strokes


Sore

$\leq 8$      $\leq 4$   
 $\leq 6$      $\leq 2$

Elixhauser index



Charlson index



# Frailty

- Syndrome that embodies an elevated risk of catastrophic declines in health and function among older adults
- Increased vulnerability to stressors
- Weakness, slowing, decreased energy, lower activity and unintended weight loss
- Fried Frailty Assessment
  - Five domains:
    - Shrinking
    - Weakness (grip strength)
    - Low energy
    - Low physical activity
    - Slowness (walking speed)
- *“The sixth age shifts into the lean and slipper’d pantaloons, with spectacles on nose and pouch on side, his youthful hose well sav’d, a world too wide, for his shrunk shank...”.*  
*Shakespeare, As You Like It*



# Walking Speed and Mortality

*How fast does the Grim Reaper Walk?*

- Concord Health and Ageing in Men Project (CHAMP)
- 1511 males > 7yrs. ROC analysis walking speed and 5 year mortality
- Walking speed of < 2 miles per hour was most predictive of mortality. Likely speed at which the Grim Reaper prefers to ambulate under working conditions.
- No men walking at speeds of > 3 miles per hour or above were caught by Death (n=22, 1.4%). This supports hypothesis that faster speeds are protective against mortality because fast walkers can maintain a safe distance from the Grim Reaper.

# Rockwood Frailty Index

## Clinical Frailty Scale\*



**1 Very Fit** – People who are robust, active, energetic and motivated. These people commonly exercise regularly. They are among the fittest for their age.



**2 Well** – People who have **no active disease symptoms** but are less fit than category 1. Often, they exercise or are very **active occasionally**, e.g. seasonally.



**3 Managing Well** – People whose **medical problems are well controlled**, but are **not regularly active** beyond routine walking.



**4 Vulnerable** – While **not dependent** on others for daily help, often **symptoms limit activities**. A common complaint is being “slowed up”, and/or being tired during the day.



**5 Mildly Frail** – These people often have **more evident slowing**, and need help in **high order IADLs** (finances, transportation, heavy housework, medications). Typically, mild frailty progressively impairs shopping and walking outside alone, meal preparation and housework.



**6 Moderately Frail** – People need help with **all outside activities** and with **keeping house**. Inside, they often have problems with stairs and need **help with bathing** and might need minimal assistance (cuing, standby) with dressing.



**7 Severely Frail** – **Completely dependent for personal care**, from whatever cause (physical or cognitive). Even so, they seem stable and not at high risk of dying (within ~ 6 months).



**8 Very Severely Frail** – Completely dependent, approaching the end of life. Typically, they could not recover even from a minor illness.



**9. Terminally Ill** – Approaching the end of life. This category applies to people with a **life expectancy <6 months**, who are **not otherwise evidently frail**.

### Scoring frailty in people with dementia

The degree of frailty corresponds to the degree of dementia. Common **symptoms in mild dementia** include forgetting the details of a recent event, though still remembering the event itself, repeating the same question/story and social withdrawal.

In **moderate dementia**, recent memory is very impaired, even though they seemingly can remember their past life events well. They can do personal care with prompting.

In **severe dementia**, they cannot do personal care without help.


\* 1. Canadian Study on Health & Aging, Revised 2008.

2. K. Rockwood et al. A global clinical measure of fitness and frailty in elderly people. CMAJ 2005;173:489-495.

# Prevalence Frailty Acute Stroke Population

- 71 acute stroke patients within 48 hours admission
- Frailty assessed using adaptation of Fried
- Multivariate model - Frailty independently associated with decline in mRS at 3 months (42% vs. 24%)
- Median length of stay;

Frail (3-5)	9 days
Pre-frail (1,2)	6 days
Non frail (0)	2 days



# Pre-stroke frailty, comorbidity and disability prevalence in stroke unit admissions

- 231 stroke unit admissions
- Pre-stroke frailty and comorbidity assessed
- 54% pre-stroke disability mRS >1
- 38% at least one marker pre-stroke frailty

Rockwood Frailty Index	
Score	Description
0	Walks unaided, independent with basic ADL*, continent of bowel and bladder, no cognitive impairment.
1	Bladder incontinence only.
2	One or more (two if bladder incontinent) of needing assistance with mobility or basic ADL, cognitive impairment with no dementia, bowel or bladder incontinence.
3	Two or more (three if bladder incontinent) of total dependence for transfers or $\geq 1$ ADL, incontinent of bladder and bowel, diagnosis of dementia.

# Disability, Frailty and Comorbidity


Frail but  
not-disabled

Rockwood Frailty Index		Pre-stroke mRS						Charlson co-morbidity Index
		0	1	2	3	4	5	
3	0	0	1	2	1	0	0	0,9
	1	1	1	6	7	9	1	
2	0	4	3	4	3	5	0	4,7
	1	0	2	17	10	5	0	
1	0	15	7	15	10	4	1	4,5
	1	2	3	7	0	1	0	
0	0	26	12	13	4	3	1	2,3
	1	85	27	5	0	0	0	
		36	7	2	1	0	0	0,1
		0	1	2	3	4	5	

**Figure 2.** Correlation between prestroke mRS and co-morbidity/frailty indices. mRS indicates modified Rankin scale.

# Pre-stroke mRS in AIS at CHUV 2003 → 2017

N=4'428 consecutive strokes



# Pre-stroke disability, dementia and stroke outcome

- Swedish dementia registry.
- Pre-stroke ADLs and mobility were worse in patients with dementia.
- In adjusted analyses, pre-stroke dementia was associated with increased 3-month mortality (OR 1.34; 95% CI 1.18–1.52).
- Patients with dementia independently mobile pre-stroke were more likely to be discharged to a nursing home compared with patients without dementia with the same pre-stroke mobility (37% vs 16%;  $P < .001$ ).
- In adjusted analyses, pre-stroke mobility limitations were associated with higher odds for poorer mobility, needing more residential assistance, and death


**Table 2**  
Prestroke Dementia in Relationship to Functional and Mortality Outcomes

	All n = 9662	Dementia n = 1689	No dementia n = 7973	P Value
In-hospital deaths	1495 (16%)	287 (17%)	1208 (15%)	.057
Survivors from hospitalization n = 8167				
Place of discharge				
Home	4465 (55%)	457 (33%)	4008 (60%)	<.001
Nursing home	2047 (25%)	712 (51%)	1335 (20%)	<.001
Geriatric rehabilitation	1453 (18%)	210 (15%)	1243 (18%)	.003
Other/still hospitalized	175 (2.1%)	14 (1%)	161 (2.4%)	<.001
Follow-up at 3 mo				
Deaths at 3 mo	2364 (25%)	526 (31%)	1838 (23%)	<.001
Survivors at 3 mo, n = 7298				
Level of residential assistance at 3 mo				
Home without help	3168 (49%)	198 (21%)	2970 (55%)	<.001
Home with help	1811 (29%)	274 (29%)	1537 (28%)	.654
Nursing home	1296 (20%)	458 (49%)	838 (16%)	<.001
Other	84 (1.3%)	12 (1.3%)	72 (1.3%)	.891
Mobility at 3 mo				
Independent	3871 (61%)	343 (37%)	3528 (66%)	<.001
Dependent outdoors	1251 (20%)	1003 (19%)	248 (27%)	<.001
Dependent indoors and outdoors	1188 (19%)	844 (16%)	344 (37%)	<.001

P values obtained from  $\chi^2$  tests. Dead at 3 months includes in-hospital deaths and deaths occurring up to 3 months after the stroke. Missing data. Mortality: none; accommodation at discharge 27 (<1%); level of residential assistance at 3 months: 939 (13%); mobility at 3 months: 988 (14%).

# Influence of comorbidity on outcome

- Pre-stroke comorbidity (Charlson Index excluding stroke, hemiplegia) in 133 women admitted with acute ischemic stroke (median NIHSS 4 range 0-22) to Duke University Medical Centre, and association with 90 day mRS outcomes. Baseline NIHSS 4.
- 9 deaths, 5 withdrawals 17 lost to follow up.
- Adjusting for NIHSS and age, higher Charlson independently associated with poorer 90 day mRS scores.
- When CI was excluded, coronary disease and diabetes were independently associated with poorer outcome.
- Limitations of study – no pre-stroke MRS assessment, unclear when patients recruited, no mRS 5/6 outcomes






# Effects of frailty, comorbidity, disability on outcomes from stroke reperfusion therapies

- Largely unknown – mostly exclude from RCTs. Most published data do not differentiate between comorbidity, frailty and disability.
- Analyses of the impact of single comorbidities on outcomes from iv thrombolysis failed to show major influence
- Reports of outcome from stroke in patients with pre stroke disability (mRS 3 and 4) suggests iv thrombolysis safe
- Single centre study 112 consecutive patients with acute ischemic stroke patients treated with IVT. 3 months outcomes patients with pre-existing disability (21% ) had increased mortality (33% v. 14% OR 3.2, 95% CI 1.0-10.1) and worse outcome (median mRS score 3 v. 2,  $p = 0.03$ ). But no difference in the total proportion of those with an mRS score of 0-1 or, for those with a pre-stroke smRS >1, a return to the pre-stroke mRS (42% v. 41%,  $p = 0.87$ )
- No systematic analysis of comorbidity burden on outcomes
- No studies of frailty on impact on efficacy and adverse effects of reperfusion therapy
- Many believe frailty might be associated with an increased risk of sICH

# Frailty and stroke prevention treatment

- HYVET study BP lowering > 80 yrs
- N=2,656 with QoL, frailty/co-morbidity assessment - 60 possible deficits
- Benefits of BP lowering present in all groups



Estimated hazard ratios for treatment effect (active treatment versus placebo) and associated 95% confidence intervals, by frailty index

Frailty index	Stroke		Cardiovascular events		Total mortality	
	HR	95% CI	HR	95% CI	HR	95% CI
0.1	0.75	0.40–1.38	0.62	0.42–0.92	0.89	0.63–1.25
0.2	0.66	0.43–1.01	0.60	0.45–0.78	0.84	0.66–1.07
0.3	0.59	0.36–0.96	0.57	0.42–0.79	0.80	0.61–1.04
0.4	0.52	0.25–1.09	0.55	0.34–0.89	0.76	0.50–1.14
0.5	0.47	0.16–1.33	0.53	0.26–1.06	0.72	0.40–1.29
0.6	0.41	0.10–1.65	0.50	0.20–1.27	0.68	0.32–1.48

All models adjusted by age, sex, and interaction between treatment and frailty index, and stratified by region of recruitment.

# A difficult case

- 72 yr old lady. Diabetes, hypertension, pseudo obstruction, seizures, cataracts, 2007 R MCA territory ischaemic stroke with residual dense left hemiparesis, left homonymous hemianopia
- Bed bound, hoisted, able to communicate with family and feed herself with right hand. Pre-stroke Modified Rankin Score 5
- Last seen well 0820h. Son went to her room 0900h found unable to speak with right sided weakness
- 0907h Call to ambulance      1006h Arrive at hospital
- Mute, aphasic, R face/arm/leg weakness. NIHSS 25 - new deficits score 7
- 1030h assessed by consultant
- 1040h CT Head – old R MCA infarct, no blood, nil acute left hemisphere

# A “poor” outcome

- Discussion with son about quality of life and her likely wishes
- 1055h Treated 165 min since last seen well
- At 24 hr communicating normally. NIHSS 18 no new deficit
- CT – small area haemorrhagic transformation HT1 left parietal cortex
- Discharged home second day following admission. Full resolution.
- Discharge Modified Rankin Score 5



# Is the comorbidity epidemic avoidable?

- Our future stroke services need to be designed to manage increasing numbers of people with comorbidity and pre-stroke disability
- Age related comorbidity can be delayed
- Cardiovascular prevention highly effective at preventing premature death and disability from stroke
- Longitudinal studies show strong associations between exercise in middle / old age and avoidance disability
- Animal studies show ageing is modifiable – caloric restriction
- Targets that could delay onset age-related disease – metabolism, inflammation, DNA repair, cell senescence,
- Increasing interest in developing drug therapies that target ageing process rather than single diseases related to ageing

Disability progression—ages 58–79 years:  
Runners' Club and Community Controls

